Two vaccines against the deadly Bundibugyo Ebola strain gripping the Democratic Republic of Congo are set to enter trials in the outbreak’s epicentre next week, the World Health Organization announced on Tuesday. … The so-called Tumaini trial in the Democratic Republic of Congo (DRC) will test the safety, efficacy and ability to trigger an immune response. The trial uses the ring vaccination method of immunising contacts deemed to be at high risk of infection. Ervebo, a vaccine already approved for use against the more common Zaire strain of Ebola, kicked off the Tumaini trial on 23 October, at the full-scale Phase 3 level, to determine if it also offers any protection against Bundibugyo. … The two Bundibugyo-specific candidate vaccines on trial have both already passed through Phase 1 clinical trials. RFI




